Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 20,092
- Locations
- 5
- Primary Endpoint
- Number of participants with circulating filarial antigenemia (CFA) as measured by the Filaria Test Strip
Study Overview
Brief Summary
This study will assess the impact of 2-drug (DA) or 3-drug (IDA) regimens on lymphatic filariasis infection parameters in communities. Parameters measured will include: circulating filarial antigenemia (CFA) assessed with the Filariasis Test Strip (FTS), antifilarial antibodies tested with plasma and microfilaremia (assessed by night blood smears and microscopy).
Detailed Description
Results from clinical trials in Papua New Guinea and Cote d'Ivoire have shown that a single dose of three drugs (ivermectin, diethylcarbamazine, and albendazole [IDA]) was superior to standard two drug therapy (diethylcarbamazine and albendazole [DA]) in clearing W. bancrofti microfilaremia (MF) (King et al. unpublished data).1 Recently, large safety studies that treated more than 23,000 participants across four countries were conducted to determine if IDA was safe for use in mass drug administration (MDA) (DOLF Project, unpublished data). Currently, there is no information about what community indicators of infection look like following shorter IDA programs. It is possible that current WHO guidelines for stopping MDA need to be modified for MDA programs that use IDA. Observing the levels of infection indicators in a community following treatment with IDA will provide important information to the GPELF if IDA is recommended for use in MDA programs. There is an opportunity to study communities that were treated with IDA during the "Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis". Communities in this study were randomly assigned to receive IDA or DA treatment. A large percentage of individuals in these communities participated in the study thereby approximating a mass distribution of the treatments. By surveying these communities 12 months following their initial treatment the investigators will be able to better understand and compare the impact of MDA with IDA or DA on LF infection parameters at the level of communities.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 5 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age ≥ 5 years (males and females)
- •Able to provide informed consent, or parental/guardian consent for young children, and assent for older children
Exclusion Criteria
- •Unable or unwilling to provide informed consent or (for minors) lacking parental/guardian consent to participate in the study
Arms & Interventions
2-Drug Treated Communities
Communities who were treated with diethylcarbamazine and albendazole (DA) mass drug administration during the safety study entitled "Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
Intervention: 2 drug dose - DA (Drug)
3-Drug Treated Communities
Communities who were treated with ivermectin, diethylcarbamazine and albendazole (IDA) mass drug administration during the safety study entitled "Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
Intervention: 3 drug dose - IDA (Drug)
Outcomes
Primary Outcomes
Number of participants with circulating filarial antigenemia (CFA) as measured by the Filaria Test Strip
Time Frame: One sample collected about 12 months after exposure to treatment
To assess the impact of DA vs. IDA mass drug administration in community settings participants will be tested using the filaria test strip (FTS) which detects circulating filarial antigen.
Number of participants with microfilaremia as measured with night blood smear testing
Time Frame: One sample collected about 12 months after exposure to treatment
To assess the impact of DA vs. IDA mass drug administration in community settings participants with positive FTS will be tested for presence of microfilaria detected by thick blood smear using 60 microliters (ul) from finger prick blood collected at night.
Number of participants with IgG4 antifilarial antibodies in plasma
Time Frame: One sample collected about 12 months after exposure to treatment
To assess the impact of DA vs. IDA mass drug administration in community settings participant's dried blood spot specimens will be tested using a commercially available antibody test.
Secondary Outcomes
- Community prevalence of microfilaremia as measured with night blood smear(One comparison about 12 months after exposure to treatment)
- Community prevalence of circulating filarial antigen as measured with filarial test strip(One comparison about 12 months after exposure to treatment)
- Prevalence of STH (hookworm, ascaris, trichuris and strongyloides) as measured by Kato-katz or PCR(One comparison about 12 months after exposure to treatment)